The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. - Wikidata - awgldk - TriplyDB

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

http://www.wikidata.org/entity/Q50156872

about

HIV infection and older Americans: the public health perspective Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?HIV and kidney diseases: 35 years of history and consequences Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Renal impairment in a rural African antiretroviral programme.Tenofovir-associated bone density loss.COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.Aging, human immunodeficiency virus, and bone health.Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine The New Epidemiology of HIV-Related Kidney Disease.Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction New approaches in the management of chronic hepatitis B: role of tenofovir.WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.HIV infection in the elderly Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.An update on the use of Atripla in the treatment of HIV in the United States.Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study.

P2860

Q26858824-F87A81E9-6AFC-447B-A7D9-B0AE0BC1ECC1 Q26995852-D9C0D8E7-5500-4797-9AAB-3919748B2A7E Q28069641-B7BF1947-1CF1-44F2-B4FB-817C4526E566 Q28533242-EAD0026B-EE98-4CFE-93B3-36434F0D3F24 Q28550681-2D93FBB4-8CA5-47D8-968A-B690924272FE Q28552839-23EB5890-8BD0-4C23-AAE6-7B7B3B6D9DCD Q28554567-6D245892-5C98-43DB-8010-2F9D6EE7D840 Q30744184-681FA5B9-5AEA-4D1D-A15D-7E7B7D824812 Q31028855-C7BCCD65-044E-4817-AA69-1726D59F0453 Q33498149-08B80514-CCF6-4B89-824E-4A71B9D9181E Q33635034-6D8B8D28-1D0B-469E-8EA7-5B3AC0D0038E Q33640397-58D789CF-FB52-4B7F-85EB-30A80ED654FD Q33845879-DA0CDEB4-F1EE-4FD0-A4F3-B7D7D222F8F5 Q34126724-5617D8D3-7E41-4D56-8CAB-9968326A6947 Q34160511-CC73125B-7121-4F56-82C5-7EE7FC97488D Q34250879-1D5398D5-9E72-43A8-BE60-5E3591CDEA5F Q34307868-9965995F-6E81-4050-95D5-A9A748423879 Q34371989-93F41494-173E-4503-9196-3A36AE346A3B Q34481359-0E353A13-ACE9-463B-B561-BDF38E29070E Q34488494-7DDAE93F-A228-41D6-A5EA-9332BE2F9E72 Q34686870-2B0F14F9-2D37-41EF-BEF4-E429146DBFFC Q34736194-B86FC919-637D-4150-A2B5-417137EBBFF4 Q34952127-8AEC04E0-0E92-460F-A1C5-321A4A34C453 Q35016654-49776D40-6A93-478C-A4DF-083C5E8705D8 Q35026531-74AAD52D-FE06-4D98-A989-EC918FBB6696 Q35040358-AA8FB96F-7F3E-4DB4-90DC-81B5880A04A5 Q35054462-8D4D8E41-71CA-428B-AABA-13703C298AEF Q35086332-012A0853-25AB-4F00-B645-190F54839334 Q35088160-9D148E2A-6069-4EC8-852B-2C0786415473 Q35091774-167CFFF6-C99A-4E3C-993F-336E04F31E65 Q35102322-D6573AE1-A4E3-4B07-ADD1-02E47ECEF67D Q35117296-4642CC06-78B9-405F-B4D7-C7716DF51C77 Q35149475-7078B670-D21F-4F97-9130-BB6E64260A5A Q35170350-3410ED5E-3857-4523-A30F-218DAF7BF67D Q35549179-459F88B7-1D11-4AB5-AACB-4C3AE1026024 Q35557269-5D1AA56B-E3A1-4CF3-BFCE-B919A8A8615C Q35575721-3EBDEDD4-CC50-4A16-A194-FF7CDDECA9FD Q35748339-6FC77170-3949-4C77-A044-CE43CC1120A0 Q35891568-550DA3E0-B5B2-4EB6-9B29-F1AC103D6A9F Q35975345-48BF960E-44F3-4B33-B2C7-BE2953FFC9C2

P2860

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

http://www.wikidata.org/entity/Q50156872

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

The safety of tenofovir disopr ...... in adults: the first 4 years.

@en

The safety of tenofovir disopr ...... in adults: the first 4 years.

@nl

type

label

The safety of tenofovir disopr ...... in adults: the first 4 years.

@en

The safety of tenofovir disopr ...... in adults: the first 4 years.

@nl

prefLabel

The safety of tenofovir disopr ...... in adults: the first 4 years.

@en

The safety of tenofovir disopr ...... in adults: the first 4 years.

@nl

P1433

Q50156872-4558C409-51C7-4872-8860-3EE58C123388

P1476

Q50156872-1134BED5-1CB8-4AB3-8DE2-98D70446EAC1

P2093

Q50156872-07899ADC-3A37-440D-9EA2-92455E0C0493

Q50156872-0BF0FACF-B60F-4888-BCB2-C07F0B81C4D1

Q50156872-394B35F6-4FD3-4918-8B1E-CC8A10EE5527

Q50156872-3E042FC6-055F-4B4B-9673-621960A83564

Q50156872-501F8509-7895-4C49-92A0-901B92F30616

Q50156872-51AF4810-D813-44ED-ABEC-0F67D66B8896

Q50156872-66973095-74D8-41AF-AA59-5A127D863F62

Q50156872-97FE6A02-9AC5-4097-AC73-E7DBF87876F0

Q50156872-982CF8E3-F82B-482E-87C3-C5BD09010EE5

Q50156872-D8C010FF-19DF-4F29-8D55-5B8C441B9EF4

P304

Q50156872-611EF108-9AD6-4A02-84ED-A5D9C24F46AD

P31

Q50156872-7875283A-D87D-45FD-BEC5-1189CD63C91C

P356

Q50156872-37E12FFC-8943-474F-80BE-5A6192D59DDC

P407

Q50156872-36EBBFB8-230C-4D7A-AE9A-707C2868DFC6

P433

Q50156872-938941BF-389B-459F-9574-EA3D538FCAEA

P478

Q50156872-98AD083A-3875-4958-836E-C3D838A1C283

P50

Q50156872-82344F90-7EBF-489A-9B46-7FA326779CC7

Q50156872-AAD0AC8D-CD1F-4699-80D9-9F6367A1E1AE

Q50156872-B2CF37CC-4043-4CE4-A420-DA3963F8B316

P577

Q50156872-AA9D93D6-0338-4F50-99FC-C25E75E5FA3D

P698

Q50156872-2CB2E960-8C96-4CA1-B160-901B57C5C698

P356

QAD.0B013E3280B07B33

P1433

P1476

The safety of tenofovir disopr ...... in adults: the first 4 years.

@en

P2093

Brian Gazzard

http://www.w3.org/2001/XMLSchema#string

Christina Wyatt

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

James F Rooney

http://www.w3.org/2001/XMLSchema#string

Joep Lange

http://www.w3.org/2001/XMLSchema#string

Julio S Montaner

http://www.w3.org/2001/XMLSchema#string

Knud Schewe

http://www.w3.org/2001/XMLSchema#string

Mark R Nelson

http://www.w3.org/2001/XMLSchema#string

Norbert Bischofberger

http://www.w3.org/2001/XMLSchema#string

Shan-Shan Chen

http://www.w3.org/2001/XMLSchema#string

P304

1273-1281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E3280B07B33

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Bonaventura Clotet Sala

Christine Katlama

Adriano Lazzarin

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17545703

http://www.w3.org/2001/XMLSchema#string